PMID- 12639217
OWN - NLM
STAT- MEDLINE
DCOM- 20030922
LR  - 20131121
IS  - 0143-5221 (Print)
IS  - 0143-5221 (Linking)
VI  - 105
IP  - 1
DP  - 2003 Jul
TI  - Decrease of serum levels of the anti-inflammatory cytokine interleukin-10 in 
      patients with advanced chronic heart failure.
PG  - 45-50
AB  - Inflammation plays a significant contributory role in the pathogenesis of chronic 
      heart failure (CHF). Many studies have shown enhanced plasma levels of 
      proinflammatory cytokines [i.e. tumour necrosis factor-alpha (TNF-alpha) and 
      interleukin (IL)-6] in patients with CHF. However, there are only few reports on 
      the regulation of anti-inflammatory cytokines such as IL-10. IL-10 has potent 
      deactivating properties in macrophages and T-cells and thus acts as a 
      down-regulator of cell-mediated immune responses. The aim of the present study 
      was to assess whether serum concentrations of IL-10 significantly differ between 
      patients with CHF and healthy control subjects. Patients with CHF [ n =50; 
      66.9+/-12.6 years; mean ejection fraction, 22.1+/-9.2%; New York Heart 
      Association (NYHA) class II-IV] and 25 healthy controls (63.6+/-10.2 years) were 
      examined. Of the 50 patients with CHF, 32 patients were taking aspirin (100 
      mg/day) and 33 patients had lipid-lowering therapy with a statin. Serum IL-10 as 
      well as TNF-alpha concentrations were measured using commercially available 
      immunoassays. Patients with CHF showed significantly lower IL-10 concentrations 
      (2.3+/-1.9 compared with 5.2+/-2.3 pg/ml; P <0.001). Patients with advanced CHF 
      (NYHA class III and IV) had the lowest IL-10 plasma levels. Aspirin and statin 
      therapy did not significantly influence serum levels of IL-10. The ratio of 
      TNF-alpha to IL-10 was significantly higher in patients with advanced CHF (NYHA 
      class III and IV, ratio 3.2+/-1.2 and 3.1+/-1.1 respectively, compared with 
      control 0.4+/-0.2; P <0.01). Our present study demonstrates significantly 
      decreased serum levels of IL-10 in patients with advanced CHF. Since IL-10 is 
      known as a potent anti-inflammatory cytokine, its decrease in advanced CHF may 
      favour the inflammatory milieu in CHF.
FAU - Stumpf, Christian
AU  - Stumpf C
AD  - Department of Cardiology, University of Erlangen-Nuremberg, Ulmenweg 18, 91054 
      Erlangen, Germany. ch.stumpf@web.de
FAU - Lehner, Christoph
AU  - Lehner C
FAU - Yilmaz, Atilla
AU  - Yilmaz A
FAU - Daniel, Werner G
AU  - Daniel WG
FAU - Garlichs, Christoph D
AU  - Garlichs CD
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Sci (Lond)
JT  - Clinical science (London, England : 1979)
JID - 7905731
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Hypolipidemic Agents)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 130068-27-8 (Interleukin-10)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Case-Control Studies
MH  - Chronic Disease
MH  - Female
MH  - Heart Failure/*blood
MH  - Humans
MH  - Hypolipidemic Agents/therapeutic use
MH  - Interleukin-10/*blood
MH  - Male
MH  - Middle Aged
MH  - Statistics, Nonparametric
MH  - Tumor Necrosis Factor-alpha/analysis
EDAT- 2003/03/18 04:00
MHDA- 2003/09/23 05:00
CRDT- 2003/03/18 04:00
PHST- 2003/03/14 00:00 [accepted]
PHST- 2003/02/11 00:00 [revised]
PHST- 2002/12/13 00:00 [received]
PHST- 2003/03/18 04:00 [pubmed]
PHST- 2003/09/23 05:00 [medline]
PHST- 2003/03/18 04:00 [entrez]
AID - CS20020359 [pii]
AID - 10.1042/CS20020359 [doi]
PST - ppublish
SO  - Clin Sci (Lond). 2003 Jul;105(1):45-50. doi: 10.1042/CS20020359.